ProKidney Corp Ordinary Shares - Class A PROK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
-
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $1.56
- Day Range
- $1.54–1.74
- 52-Week Range
- $1.12–4.85
- Bid/Ask
- $1.65 / $1.72
- Market Cap
- $213.66 Mil
- Volume/Avg
- 428,205 / 686,676
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 4.45%
Company Profile
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 163
- Website
- https://www.prokidney.com
Comparables
Valuation
|
Metric
|
PROK
|
4592
|
FOLD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 51.78 | 23.72 |
Price/Sales | — | — | 7.00 |
Price/Cash Flow | — | — | — |
Price/Earnings
PROK
4592
FOLD
Financial Strength
|
Metric
|
PROK
|
4592
|
FOLD
|
|---|---|---|---|
Quick Ratio | 21.09 | 4.75 | 2.05 |
Current Ratio | 21.87 | 5.30 | 2.75 |
Interest Coverage | −15,395.90 | −202.54 | −1.09 |
Quick Ratio
PROK
4592
FOLD
Profitability
|
Metric
|
PROK
|
4592
|
FOLD
|
|---|---|---|---|
Return on Assets (Normalized) | −27.43% | −46.86% | −4.50% |
Return on Equity (Normalized) | — | −95.71% | −25.21% |
Return on Invested Capital (Normalized) | −33.56% | −73.10% | 0.28% |
Return on Assets
PROK
4592
FOLD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Yfgrvhgyp | Bbz | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Sdnyhmsr | Fnjvmy | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jqhgsqv | Wjbvsr | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gsbwlnflh | Xlgfb | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Thdnymxz | Jpwqv | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Nnxmgxywd | Cfvd | $29.2 Bil | |||
| Moderna Inc
MRNA
| Yxghcmzw | Brcy | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Httyrrsz | Vgzs | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ppjnrgqb | Mnblkbw | $13.2 Bil | |||
| Incyte Corp
INCY
| Yxbhcbxhp | Ldcmcs | $13.0 Bil |
United States